NURO (NeuroMetrix Corp) שולי הרווח הגולמי

Sales of Quell neurostimulators and diagnostic systems for neurologists ensure stable demand, confirming the sector's macro-resilience driven by insurance payouts. The share of gross income in revenue visualizes current profitability, with the 55.40 mark reflecting the latest data. However, a deep operational crisis and reliance on a single product are forcing NeuroMetrix, Inc. (NURO) to liquidate assets to preserve capital.
פילוחים אנליטיים ודוחות נתונים של חברת NeuroMetrix (NURO)

NeuroMetrix, Inc. (NURO) relies on organic resource optimization and limited retail sales of medical devices, which determines its current operational efficiency. This ratio digitizes the portion of revenue remaining after covering direct production costs, revealing the actual profitability of each unit. Analyzing the gross margin vector allows for the filtering of information noise and an assessment of the business's fundamental stability without relying on management declarations.